Investment Q&A

Q: What’s your outlook on this stock ?

Q: Could provide any insight into why SVI has dropped hard in the last six weeks, down approximately 24%. Is this a buying opportunity or a falling knife?
Thank you, Mike

Q: Hi 5i Aurinia pharma seems to have turned the corner with earnings and is also getting the drug into hospitals They are again reducing staff this time by 45%. They also have a new drug in trails. Please put on your speculative hat for the questions.

-would drug (Lupkynis) be of interest at this stage in development for another company to buy them and what would the buyout price be for the right company.
-going forward they will make about $220,000,000 a year this took about 3 1/2 years with a covid launch, what do you see max sale's being with the current set up and how many years to get there.
-Do you think Aurinia is a good speculative buy.

Thank you for your service!

Q: Hello 5i

Can you talk about the insider ownership of WELL and the major holders of the shares please ?

And why are CIBC World Markets' expectations of $5.25 on 08/11/2024 so low?

Thanks

Q: Given our best guesses of what Trump 2.0 is likely to mean….three best Canadian small cap ideas please.

Q: Pretty nice earnings, but with other issues noted on previous questions what fair value would you place on the shares at this point?

Q: On Monday morning it was at 29 dollars and now Wednesday morning it is at 22.70. There was no news. Im assuming it was because of Trumps tariff plans. Do you believe this is an over reaction and a good buying opportunity especially after the impressive release of q3.

Q: An update please on your opinion and outlook for GOLD.
Thanks

Q: Is FCU a buy for a uranium play ? It is cheap RAK

Q: recent earnings and outlook comment

Q: Many updates since the last review of this company. With new shares being issued at $4.75 I would hope this provides a level of support, but not sure I should be holding hoping to see results vs selling now after a nice run and waiting for the results first and then reinvesting.

Q: I would like your thoughts on MCan Financial today. Their results were good, but are they worth the jump today? They sold shares earlier in the year which got me nervous, but it seems like they are delivering.

Q: Is there an ETF in CAD { unhedged } that you would recommend that follows the Russel 2000?

Thanks

Q: Is Pres Trump pro Nuclear, I think he prefers Smaller Nuclear Plants With AI and EVS USA will need more power Is Nuclear the answer.

How to play please RAK

Q: Just speculating on the possibility that propel could be bought out by one of the major banks in Canada-I don’t believe they offer a similar type of business and this seems like way to diversify a little

Q: You have liked these small/mid cap names over past couple of years and most have done well, thank you.

Under current market conditions and entering a second Trump Term, what would be the order that you would buy these names? Is there any of these names you would not buy and move on from?

Thank You
Tim

Q: Peter and His Wonder Team
It looks like they just made a good acquisition. In the past it was a $68.00 stock now trading at $15.00. Please give your assessment and does it look like a reasonable buy? Thanks as always for your help!

Q: As per my question back in July the value of the options are supposed to be accounted for on a quarterly basis in the payables. Directly to my question if we were ganna have to wait many more years before they have little effect on the financials, your answer was:

``Much of these expenses are reported on the financial statements each quarter at fair value, and so although they might have a vesting period of three to five years, the fair value expense of these are recorded. When the DSUs vest, there should not be a material change to the income statement since the options were already accounted for using their fair value over the previous financial statements.

Even though the stock price has risen dramatically over the years, this increase has been accounted for on the financial statements already. A decrease in share price quarter-to-quarter can actually benefit the financials as the fair value of these expenses can decline. ``

What happened in the last quarter reporting then? Weren't the options valued correctly just 3 months ago?

Hard for me to wrap my head around this situation with HPS. It just feels that there is more money flowing into the pockets of the directors at the cost of my investment.

Yves

Q: your view on recent earnings report
thank you

Q: Investors disliked Mcb's latest Q resulting in Nov 8 close at $2.83 - 0.60. Please comment on Q results and going forward.Saw u comments on Nov 7 prior to Q.Buy,Hold or Sell. Txs for U usual great services & views.